Meeting Coverage:

American Academy of Ophthalmology

AAO: 2017

The Future of Cross-linking

Show Description +

William Trattler, MD, explains why he is looking forward to the FDA approval of epithelial-on cross-linking (epi-on CXL). Dr. Trattler says that epi-on CXL provides increased safety and faster visual recovery compared to epithelial-off CXL.

Posted: 11/12/2017

Up Next


Should We Still Be Doing DSAEK?

Winston Chamberlain, MD, PhD

Hot Topic: Pharmaceutical Compounding

Keith Walter, MD, Nathan Radcliffe, MD, Tal Raviv, MD

Hot Topic: Successful Collaborations

Constance Okeke, MD, Greg Parkhurst, MD, John Berdahl, MD

Suprachoroidal Steroids for DME

Charles Wykoff, MD, PhD

Gene Therapy for Wet AMD

Szilárd Kiss, MD

Head-to-Head Trials

Pravin Dugel, MD

Who, What, Where, and When?

Arsham Sheybani, MD, Ike Ahmed, MD

An Update on GATT

Davinder Grover, MD

Who Should Perform MIGS?

Michael Patterson, DO

Hot Topic: Is Astigmatism Correction a Must?

George Waring IV, MD, Neel Desai, MD, Zaina Al-Mohtaseb, MD

Updates on Sjögren Syndrome

Stephen Pflugfelder, MD

Who Should Perform MIGS?

Osamah Saeedi, MD

Hot Topic: Technologies in 2018

Robert Weinstock, MD, Roger Zaldivar, MD

The Future of Cross-linking

William Trattler, MD, explains why he is looking forward to the FDA approval of epithelial-on cross-linking (epi-on CXL). Dr. Trattler says that epi-on CXL provides increased safety and faster visual recovery compared to epithelial-off CXL.

Posted: 11/12/2017


Please log in to leave a comment.

More From AAO: 2017 Coverage

Suprachoroidal Steroids for DME

Charles Wykoff, MD, PhD

Gene Therapy for Wet AMD

Szilárd Kiss, MD